VTYX
Ventyx Biosciences, Inc.
NASDAQ · Healthcare · Biotechnology · US
$14.00
+0.00%0
Insider buys (3m)
0
Insider sells (3m)
$0.00
Net value (3m)
+52.5%
Price return (3m)
Form 4 filings
| Date | Insider | Activity | Shares | Price |
|---|---|---|---|---|
| Dec 19, 2025 | Mohan Raju · director, officer: CEO AND PRESIDENT | M-Exempt | 116,668 | $0.00 |
| Dec 19, 2025 | Mohan Raju · director, officer: CEO AND PRESIDENT | Sale | 47,345 | $7.72 |
| Dec 19, 2025 | Nuss John · officer: CHIEF SCIENTIFIC OFFICER | M-Exempt | 34,930 | $0.00 |
| Dec 19, 2025 | Nuss John · officer: CHIEF SCIENTIFIC OFFICER | Sale | 12,675 | $7.72 |
| Nov 19, 2025 | Forman Mark S · officer: Chief Medical Officer | A-Award | 3,000 | $1.03 |
| Nov 19, 2025 | Gonzales Roy · officer: Senior VP, Finance | A-Award | 1,767 | $1.03 |
| Jun 6, 2025 | Cadoret-Manier Onaiza · director | A-Award | 40,000 | $2.25 |
| Jun 6, 2025 | HULME ALLISON · director | A-Award | 40,000 | $2.25 |
| Jun 6, 2025 | Subramaniam Somu · director | A-Award | 40,000 | $2.25 |
| Jun 6, 2025 | White William Richard · director | A-Award | 40,000 | $2.25 |
| Jun 6, 2025 | Gujrathi Sheila · director | A-Award | 40,000 | $2.25 |
| May 16, 2025 | Gonzales Roy · officer: Senior VP, Finance | A-Award | 1,750 | $1.03 |
| May 16, 2025 | Forman Mark S · officer: Chief Medical Officer | A-Award | 3,000 | $1.03 |
| Apr 3, 2025 | Nuss John · officer: CHIEF SCIENTIFIC OFFICER | Sale | 1,887 | $1.07 |
| Apr 1, 2025 | Mohan Raju · director, officer: CEO AND PRESIDENT | M-Exempt | 11,844 | $0.00 |
| Apr 1, 2025 | Nuss John · officer: CHIEF SCIENTIFIC OFFICER | M-Exempt | 4,531 | $0.00 |
| Jan 3, 2025 | Nuss John · officer: CHIEF SCIENTIFIC OFFICER | A-Award | 245,000 | $2.14 |
| Jan 3, 2025 | Nuss John · officer: CHIEF SCIENTIFIC OFFICER | A-Award | 170,104 | $2.14 |
| Jan 3, 2025 | Mohan Raju · director, officer: CEO AND PRESIDENT | A-Award | 700,000 | $2.14 |
| Jan 3, 2025 | Moore Matthew Richard · officer: Chief Operating Officer | A-Award | 145,000 | $2.14 |
| Jan 3, 2025 | Gonzales Roy · officer: Senior VP, Finance | A-Award | 109,200 | $2.14 |
| Jan 3, 2025 | Gonzales Roy · officer: Senior VP, Finance | A-Award | 17,500 | $2.14 |
| Jan 3, 2025 | Forman Mark S · officer: Chief Medical Officer | A-Award | 85,000 | $2.14 |
| Dec 30, 2024 | Nuss John · officer: CHIEF SCIENTIFIC OFFICER | Sale | 21,119 | $2.36 |
| Dec 26, 2024 | Gujrathi Sheila · director | Purchase | 130,000 | $2.31 |
| Dec 19, 2024 | Nuss John · officer: CHIEF SCIENTIFIC OFFICER | M-Exempt | 34,930 | $0.00 |
| Dec 19, 2024 | Nuss John · officer: CHIEF SCIENTIFIC OFFICER | Sale | 13,161 | $2.26 |
| Dec 19, 2024 | Mohan Raju · director, officer: CEO AND PRESIDENT | M-Exempt | 116,668 | $0.00 |
| Dec 11, 2024 | Nuss John · officer: CHIEF SCIENTIFIC OFFICER | M-Exempt | 193,557 | $0.20 |
| Dec 11, 2024 | Nuss John · officer: CHIEF SCIENTIFIC OFFICER | M-Exempt | 5,377 | $0.20 |
Institutional positioning
13F filings over the trailing two quarters
New 0Increased 1Reduced 0Sold out 4
| Filer | Action | Shares | Filed |
|---|---|---|---|
| GOLDMAN SACHS GROUP INC | Increased | 837,602 | Mar 25, 2026 |
| GOLDMAN SACHS GROUP INC | Sold Out | 0 | Mar 25, 2026 |
| Opaleye Management Inc. | Sold Out | 0 | Apr 13, 2026 |
| Basecamp Wealth Advisors LLC | Sold Out | 0 | Jun 24, 2026 |
| MORGAN STANLEY | Sold Out | 0 | May 27, 2026 |
Insider activity from SEC Form 4; institutional positioning from 13F filings · Latest filing Dec 19, 2025